This interactive event brought together leading experts to explore the value of holistic, multidisciplinary care for patients with Inflammatory Bowel Disease (IBD) and discuss the use of the preferential Janus kinase 1 (JAK1) inhibitor Jyseleca^®▼ (filgotinib) for moderate to severe Ulcerative Colitis (UC). Built to be audience led, attendees voted for the data and perspectives they most wanted to hear.

This exciting session showcases:

• Nine expert faculty
• Two real-world case examples
• Audience-guided content
• Practice-focussed discussion

Presented by:
Axel Dignass, MD, PhD – Frankfurt, Germany
Iris Dotan, MD – Petah Tikva, Israel
James Lindsay, PhD, BM BCh, FRCP – London, UK

Conventional therapies remain the most common first-line treatments for moderate to severe ulcerative colitis (UC) in the EU, including aminosalicylates (5-ASAs), corticosteroids, and immunosuppresants.¹ However, clinical remission is not always achieved with conventional therapies in certain patient populations.² According to one retrospective study of patient-reported outcomes of 256 patients, more than half of patients did not achieve control of clinical measures, such as rectal bleeding or normal stool frequency, with the use of conventional therapies.²